# EndoCell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/endocell

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Total disclosed funding: $24M
- Latest round: Series A (May 5, 2025)
- Investors on record: 3

## About

Established in 2019 and based in Shanghai, China, EndoCell is a regenerative islet research and development company focuses on the in vitro regeneration technology of human tissues and organs. FounderXin Cheng is from the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences. In April 2025, the first product pipeline, allogeneic human regenerative islet injection (E-islet 01), acquired IND clinical approval from the National Medical Products Administration. In May 2025, it raised CNY 100 million in series A funding co-led by new investors Shanghai STVC Group and Lingang Digital Technology Fund.

The company's main product line is regenerative pancreatic islet transplantation. It also provides in vitro reconstruction of human tissues and organs.

The company generates revenue by providing in vitro reconstructed pancreatic islet tissue.

The company will use the funds to conduct Phase I/II clinical trials of its allogeneic universal regenerated islet pipeline, accelerate strategic deployment, and develop new pipelines for the treatment of diabetes and liver disease.

## Funding rounds

- Series A, May 5, 2025, $14M — Shanghai STVC Group, Lingang Digital Technology Fund
- Angel, Sep 10, 2021, $10M — Kaitai Capital

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Angel
- Shanghai STVC Group (https://capitalatlas.ai/funds/shanghai-stvc-group) — Series A
- Lingang Digital Technology Fund (https://capitalatlas.ai/funds/lingang-digital-technology-fund) — Series A